Literature DB >> 30154124

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.

Gil Awada1, Teofila Seremet1,2, Karel Fostier3, Hendrik Everaert4, Bart Neyns1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30154124      PMCID： PMC6113614          DOI： 10.1182/bloodadvances.2018021782

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

3.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Authors:  James Larkin; Paolo A Ascierto; Brigitte Dréno; Victoria Atkinson; Gabriella Liszkay; Michele Maio; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Mika A Sovak; Ilsung Chang; Nicholas Choong; Stephen P Hack; Grant A McArthur; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

4.  The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis.

Authors:  Masayuki Kobayashi; Arinobu Tojo
Journal:  Blood       Date:  2014-10-16       Impact factor: 22.113

Review 5.  Histiocytoses: emerging neoplasia behind inflammation.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Barret J Rollins; Jean Donadieu; Frédéric Charlotte; Ahmed Idbaih; Augusto Vaglio; Omar Abdel-Wahab; Jean-François Emile; Zahir Amoura
Journal:  Lancet Oncol       Date:  2017-02       Impact factor: 41.316

Review 6.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

7.  Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Authors:  David M Hyman; Eli L Diamond; Cecile Rose T Vibat; Latifa Hassaine; Jason C Poole; Minal Patel; Veronica R Holley; Goran Cabrilo; Timothy T Lu; Maria E Arcila; Young Rock Chung; Raajit Rampal; Mario E Lacouture; Neal Rosen; Funda Meric-Bernstam; José Baselga; Razelle Kurzrock; Mark G Erlander; Filip Janku; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2014-10-16       Impact factor: 39.397

8.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Authors:  Georgina V Long; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Adil Daud; Rene Gonzalez; Jeffrey A Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Richard F Kefford; Donald Lawrence; Ragini Kudchadkar; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Igor Puzanov; Nageatte Ibrahim; Peng Sun; Elizabeth Cunningham; Amy S Kline; Heather Del Buono; Diane Opatt McDowell; Kiran Patel; Keith T Flaherty
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

9.  Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Authors:  Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.

Authors:  Max Schreuer; Geert Meersseman; Sari Van Den Herrewegen; Yanina Jansen; Ines Chevolet; Ambre Bott; Sofie Wilgenhof; Teofila Seremet; Bart Jacobs; Ronald Buyl; Geert Maertens; Bart Neyns
Journal:  J Transl Med       Date:  2016-04-19       Impact factor: 5.531
View more
  7 in total

1.  BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.

Authors:  Rosemarie Mastropolo; Allison Close; Steven W Allen; Kenneth L McClain; Scott Maurer; Jennifer Picarsic
Journal:  Blood Adv       Date:  2019-06-25

2.  Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.

Authors:  Antonious Z Hazim; Gordon J Ruan; Aishwarya Ravindran; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Oncologist       Date:  2020-10-12

Review 3.  Adult Langerhans Cell Histiocytosis and the Skeleton.

Authors:  Danae Georgakopoulou; Athanasios D Anastasilakis; Polyzois Makras
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

4.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490

5.  Langerhans Cell Histiocytosis: Single Center Experience of 25 Years.

Authors:  G Tuysuz; I Yildiz; N Ozdemir; I Adaletli; S Kurugoglu; H Apak; S Dervisoglu; S Bozkurt; T Celkan
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-05-01       Impact factor: 2.576

6.  Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis.

Authors:  Ying Yang; Dong Wang; Lei Cui; Hong-Hao Ma; Li Zhang; Hong-Yun Lian; Qing Zhang; Xiao-Xi Zhao; Li-Ping Zhang; Yun-Ze Zhao; Na Li; Tian-You Wang; Zhi-Gang Li; Rui Zhang
Journal:  Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.679

7.  High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.

Authors:  Lynn H Lee; Christa Krupski; Jason Clark; Mark Wunderlich; Robert B Lorsbach; Michael S Grimley; Matthew Burwinkel; Adam Nelson; Ashish R Kumar
Journal:  Blood Adv       Date:  2020-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.